-
3 days ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. A ban on pharma’s TV ads may finally be on the way. Sens. Bernie Sanders, I-Vt., and Angus King, I-Maine, introduced the End Prescription Drug Ads Now Act last week that would end pharma’s ability to advertise directly to consumers. If enacted, the bill would fulfill a goal of HHS Secretary Robert F.
-
5 days ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. Pharma’s middlemen are under fire. Known as the negotiators between health plans, pharmacies and drug companies, pharmacy benefit managers are currently entangled in a national conversation about reform. The pharma industry has long blamed PBMs for rising drug prices, pointing to opaque rebate and profit structures, and proposed policy shifts could take them to task.
-
1 week ago | 
biopharmadive.com | Amy Baxter
The budget bill currently under consideration in Congress is big — and it’s complicated. The 1,000-plus page document is full of tax and spending cuts, including some significant changes that will impact pharma and the larger healthcare industry. The legislation, which was narrowly approved in the House last month and is now in the hands of the Senate, includes reforms to pharmacy benefit managers and the Inflation Reduction Act. But the bill’s path forward is uncertain.
-
1 week ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. The budget bill currently under consideration in Congress is big — and it’s complicated. The 1,000-plus page document is full of tax and spending cuts, including some significant changes that will impact pharma and the larger healthcare industry.
-
1 week ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. Two industry leaders currently define the obesity market: Novo Nordisk and Eli Lilly — the only companies with approved GLP-1s. But dozens of hopefuls are advancing candidates through the clinic with the goal of edging better drugs to the market. Not all new obesity assets will create a gold mine.
-
2 weeks ago | 
biopharmadive.com | Amy Baxter
The Food and Drug Administration aims to roll out its new AI tool, called Elsa, “ahead of schedule and under budget,” according to Commissioner Marty Makary, who offered up the most information to date about the agency’s new tool and AI goals this week. After completing a pilot program of AI-assisted scientific reviews last month, the FDA announced it was taking an “aggressive” approach to scale up the use of Elsa agency-wide by June 30. That timeline moved up this week.
-
2 weeks ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. The FDA plans to roll out its new AI tool, called Elsa, “ahead of schedule and under budget,” according to Commissioner Dr. Marty Makary, who offered up the most information to date about the agency’s new tool and AI goals this week. But questions remain.
-
2 weeks ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. The GLP-1 boom isn’t slowing down anytime soon. Prescriptions for overweight or obese adults jumped almost 587% from 2019 to 2024, Healthcare Dive reported, and there’s still a huge untapped patient population representing more market upside. As pharma’s pipeline explodes with more than 100 new drugs in various stages of development, one barrier to access has yet to be toppled.
-
3 weeks ago | 
sailingworld.com | Amy Baxter
Abie McLaughlin, age 38, had a breakout year in 2024, achieving a hat trick of North American championship wins in the J/88, Tartan 10 and S2 7.9 classes. Having quickly earned a reputation as a skilled and dedicated amateur sailor, she is now in demand as one of the best foredeck crews you’ve never heard of—until now. McLaughlin’s low-key personality has kept her under the radar.
-
3 weeks ago | 
pharmavoice.com | Amy Baxter
This audio is auto-generated. Please let us know if you have feedback. Following through on President Donald Trump’s “most favored nation” policy, the HHS is about to drop a drug pricing hammer on the pharma industry. But that doesn’t mean drugmakers will comply. The policy, issued by an executive order earlier this month in an attempt to bring U.S. drug prices in line with those paid in other countries, asks drugmakers to voluntarily lower their own price tags first.
